Lung cancer remains the leading cause of cancer death worldwide. For decades, we believed it was mainly caused by smoking and genetic mutations. While mutations are still important, new research shows they are only part of the story. Inflammation may be the missing link.
Scientists are now studying whether anti-inflammatory drugs could help treat — and even prevent — lung cancer. The idea is simple but powerful: if inflammation helps cancer grow, stopping inflammation may stop cancer too.
Why Inflammation Matters in Lung Cancer
Our bodies naturally develop abnormal cells every day. In most cases, the immune system finds and removes them before they become dangerous. So why does cancer sometimes develop?
Recent research suggests that mutations alone are not enough. Cancer cells also need a “permissive environment” to grow. Chronic inflammation creates that environment.
Inflammation in the lungs can be triggered by:
- Cigarette smoke
- Air pollution
- Environmental toxins like asbestos
- Chronic lung disease
- Ongoing immune activation
When inflammation becomes long-term, immune cells release molecules that can promote tumor growth, blood vessel formation, and cancer spread.
One key inflammatory molecule is interleukin-1 beta (IL-1β). This molecule is part of the body’s natural immune response, but when overactive, it may help lung tumors grow and spread.
The Breakthrough Study That Changed the Conversation
A large clinical trial originally designed to prevent heart disease made an unexpected discovery. Researchers tested a drug called canakinumab, which blocks IL-1β, in more than 10,000 patients with heart disease.
The goal was to reduce cardiovascular events. But something surprising happened.
Patients receiving higher doses of the anti-inflammatory drug had:
- Fewer new cases of lung cancer
- Lower lung cancer death rates
- A dose-dependent reduction in risk
The strongest results were seen in patients who achieved the greatest reductions in inflammation markers like C-reactive protein (CRP) and interleukin-6.
Importantly, the drug did not significantly reduce other types of cancer. The effect appeared strongest in lung cancer.
This finding suggested that blocking inflammation — specifically the IL-1β pathway — may interfere with lung cancer development or progression.
Mutation Alone Is Not Enough
Emerging research in cancer biology shows that many people accumulate mutations as they age — even in healthy tissues. Yet not all mutations lead to cancer.
Scientists now believe inflammation plays a key role in deciding whether mutated cells stay controlled or become malignant.
In simple terms:
- Mutations may light the match.
- Inflammation may fuel the fire.
If inflammation is necessary for cancer initiation, then reducing inflammation could be a powerful prevention strategy.
Researchers are calling this approach “cancer interception” — stopping cancer before it fully develops.
Could Anti-Inflammatory Drugs Be Used for Prevention?
The idea of using anti-inflammatory therapy to prevent lung cancer is gaining attention. However, several important questions remain.
Who should take these medications?
Not everyone with lung inflammation will develop cancer. Many people develop pre-cancerous lung lesions that never progress.
Researchers are now exploring:
- Blood tests that measure inflammation levels
- Biomarkers to identify high-risk individuals
- Imaging combined with inflammatory markers
The goal is precision prevention — treating only those most likely to benefit.
Potential Benefits and Risks
Blocking inflammation is not without risk. In the large trial, patients taking canakinumab had:
- Higher rates of serious infections
- Increased risk of sepsis
Because IL-1β plays a role in fighting infection, suppressing it can weaken immune defenses.
This means any preventive strategy must balance:
- Cancer risk reduction
- Infection risk
- Cost and long-term safety
Researchers are now testing lower-risk anti-inflammatory approaches and exploring whether combining therapies could improve safety.
What This Means for the Future of Lung Cancer Care
This new understanding changes how we think about lung cancer.
Instead of focusing only on:
- Smoking cessation
- Mutation-targeting drugs
- Late-stage tumor treatment
We may begin focusing more on:
- Monitoring inflammation
- Intervening earlier
- Preventing progression before cancer spreads
This approach could be especially important for:
- Former smokers
- People with chronic lung inflammation
- Individuals with elevated inflammatory markers
Clinical trials are now underway to test anti-inflammatory strategies in lung cancer prevention and early-stage disease.
The Bottom Line
Lung cancer does not develop from mutations alone. Chronic inflammation appears to play a critical role in helping cancer take hold and spread.
A large clinical trial showed that blocking the inflammatory molecule IL-1β reduced lung cancer incidence and death rates. This discovery has opened the door to a new prevention strategy focused on controlling inflammation.
While more research is needed, anti-inflammatory drugs may one day become part of lung cancer prevention — especially for high-risk patients.
The future of lung cancer care may not just be about killing tumors. It may be about stopping the conditions that allow them to grow in the first place.
Sources
Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833–1842. Available from: https://www.thelancet.com
Nature. Anti-inflammatory drugs and lung cancer prevention. 2026. Available from: https://www.nature.com/articles/d41586-026-01382-2
